Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2016

View Archived Issues

Novel S1P1 and S1P5 selective agonists identified for the treatment of autoimmune disease

Suven presents potent and selective H3R ligands with cognition-enhancing potential

DUOC-01 cells accelerate brain remyelination in vivo

Basilea Pharmaceutica patents MAPK inhibitors

F. Hoffmann-La Roche discloses HBsAg inhibitors

Chiesi develops compounds with mAChR antagonistic and beta2-adrenoceptor agonist activity

Merck Patent describes IRAK inhibitors

AbbVie reports SUV420H1 inhibitors

Early AR-101 immunotherapy is safe and effective in peanut-allergic preschool children

Researchers aim to find therapies for patients with hard-to-treat lymphomas

FDA gives favorable feedback to Corium's pre-IND application for Corplex memantine

FDA grants orphan drug designation to TG Therapeutics' TGR-1202

Ardelyx identifies promising gut-restricted TGR5 agonists

Insys Therapeutics reports positive results in phase III trial of buprenorphine sublingual spray

Abcellera Biologics completes antibody discovery partnership with Kodiak Sciences

Amgen receives FDA complete response letter for Parsabiv

Nymox Pharmaceutical announces positive results on fexapotide phase III trial

Mallinckrodt to sell its nuclear imaging business to IBA Molecular

Biothera expands collaboration with Merck & Co. for Keytruda combination study

FDA grants orphan drug designation to Scynexis' SCY-078 antifungal agent

FDA grants orphan drug designation to SFX-01 for the treatment of subarachnoid haemorrhage

Immix Biopharma completes stability testing for Imx-110

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...